Clinical Trials
3 trialsNCT04909515 2022-09-01
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.
Y-mAbs Therapeutics
Phase 2 Withdrawn
NCT00003405 2021-10-14
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia
Rush University Medical Center
Phase 2 Withdrawn
NCT01048086 2016-06-21
90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET)
University of Iowa
Phase 2 Withdrawn